Alpha Thalassemia Market Research Report - Global Forecast till 2023

Alpha Thalassemia Market Research Report - Global Forecast till 2023

ID: MRFR/HC/3712-HCRR | January, 2018 | Region: Global | 90 pages | Half-Cooked Research Reports

Alpha thalassemia market research report: by type (hb bart syndrome, hbh disease, silent carrier state, and trait.), by diagnosis (perinatal testing, prenatal testing, and pre-implantation), by treatment, by end user – Global forecast till 2023 


Market Scenario


Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two proteins called alpha globin and beta globin. A person is required to inherit a total of four genes to produce alpha globin protein, two of these genes are inherited from the parents. This blood disorder is caused due to abnormality or mutation in one or more genes responsible for hemoglobin production. When a person inherits only one affected gene from parents then the person becomes a carrier of thalassemia. Since thalassemia is an inherited disorder; one of the parents must be a carrier for thalassemia. When both the parents are carriers then the risk of giving birth to a thalassemia affected child is quite high. Thalassemia is generally of two types: alpha thalassemia and beta thalassemia.


Alpha thalassemia is a blood disorder that reduces the production of hemoglobin. Hb Bart syndrome is the most commonly occurring type which is characterized by hydrops fetalis, a condition in which excess fluid builds up in the body before birth.


Globally, thalassemia affects approximately 7% of the population out of which its alpha type affects 3% with many of them being transfusion-dependent patients. The global alpha thalassemia market is likely to be driven by the growing market of bone marrow transplant and blood transfusion therapy, supported by high numbers of transfusion-dependent patients. Key trends in this market include progressing drug pipeline, rising scope of gene therapy and growing awareness towards thalassemia. However, there are some factors which can hinder the growth of the market including regulatory changes, associated risks and the high cost of treatment.


The global market for alpha thalassemia is expected to grow at a CAGR of approximately 8.8% during the forecast period 2017-2023.


Intended Audience



  • Alpha thalassemia drug Suppliers

  • Alpha thalassemia drug Manufacturers

  • Research And Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation


The alpha thalassemia is segmented on the basis of type, diagnosis, treatment, and end-users.


On the basis of the type, the market is segmented into hemoglobin Bart hydrops fetalis syndrome or Hb Bart syndrome (the more severe form), HbH disease, silent carrier state, and trait.


On the basis of the diagnosis, the market is segmented into perinatal testing, prenatal testing, and pre-implantation. Further, the perinatal testing sub-categorized into complete blood count (CBC) And DNA testing. The prenatal testing further sub-segment into prenatal genetic testing and chorionic villus sampling. 


On the basis of the treatment, the market is segmented into blood transfusions, iron chelation, bone marrow, or stem cell transplant, surgery and gene therapy.


On the basis of the end-user, the market is segmented into hospitals, biotechnological laboratories, diagnostic laboratories, educational research institutes, pharmaceutical industries and others.


Regional Analysis


The global alpha thalassemia market consists of regions namely Americas, Europe, Asia Pacific, the Middle East and Africa


North America is projected to hold the largest share of the global alpha thalassemia market due to the presence of superior research and development base, strong regional economies, and greater emphasis on disease prevention and wellness by the governments. The U.S. is expected to be the first region to start selling thalassemia drugs due to developing drug pipeline and later on, market penetration of thalassemia drugs would occur in Europe. North America and Europe have a high prevalence of severe forms of alpha-thalassemia which would result in a high demand for thalassemia drugs in future.


The tropical regions are more prone to possess high numbers of patients with alpha thalassemia like Nigeria, Sudan, Chad, Columbia etc. followed by few South Asian countries. Research Institutes and Pharmaceutical companies, growing usage for alpha thalassemia testing and technological advancements, rising awareness are few factors driving market growth in the region. Few Asian countries like Myanmar and Thailand also have a high number of alpha thalassemia patients.


The key factors which are anticipated to drive this market include rising healthcare expenditure, rising spending on stem cell therapy research and development and rising population in the East-Asia and Pacific region of the world. Some of the noteworthy developments of this industry include the advances in the iron chelation therapy, development of gene therapy and fetal hemoglobin inducers as potential curatives for thalassemia. However, the growth of the respective industry is challenged by the high cost of treatments, lack of alternative treatments and unmet market of the Asia-Pacific. The thalassemia market is expected to grow in future with the mounting prevalence of thalassemia, rising Asian population, increasing healthcare expenditure, rising spending on pharmaceuticals R&D and stem cell therapy research.


The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.


Key Players


Some of key the players in the global alpha thalassemias market are GlaxoSmithKline Plc, Celgene, Bellicum Pharmaceuticals, Lonza group, Acceleron Pharma, BlueBird Bio, Sangamo Biosciences.


The other prominent players include Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Calimmune Inc, CRISPR Therapeutics, Editas Medicine Inc, Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc, Incyte Corp, Ionis Pharmaceuticals Inc, IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc, PharmaEssentia Corp, Protagonist Therapeutics Inc, Sangamo Therapeutics Inc and Zydus Cadila Healthcare Ltd.


Research Methodology

Alpha Thalassemia Market


Sources: Annual reports, Press release, White paper, and Company presentation





TABLE OF CONTENT 

 

Chapter 1.       Report Prologue

 

Chapter 2.        Market Introduction      

 

2.1        Definition        

 

2.2        Scope of the Study     

 

2.2.1     Research Objective     

 

2.2.2     Assumptions   

 

2.2.3     Limitations      

 

Chapter 3.         Research Methodology

 

3.1        Introduction

 

3.2        Primary Research        

 

3.3        Secondary Research     

 

3.4        Market Size Estimation

 

Chapter 4.         Market Dynamics

 

4.1        Drivers

 

4.2        Restrains

 

4.3        Opportunities  

 

4.4        Challenges

 

4.5        Macroeconomic Indicators

 

4.6        Technology Trends & Assessment                               

 

Chapter 5.         Market Factor Analysis

 

5.1        Porter’s Five Forces Analysis

 

5.1.1     Bargaining Power of Suppliers 

 

5.1.2     Bargaining Power of Buyers

 

5.1.3     Threat of New Entrants

 

5.1.4     Threat of Substitutes   

 

5.1.5     Intensity of Rivalry       

 

5.2        Value Chain Analysis

 

5.3        Investment Feasibility Analysis 

 

5.4        Pricing Analysis

 

Chapter 6.         Global Alpha Thalassemia Market, By Type

 

6.1        Introduction

 

6.2        Hb Bart syndrome

 

6.2.1     Market Estimates & Forecast, 2016 – 2023

 

6.3        HbH disease

 

 6.3.1    Market Estimates & Forecast, 2016 – 2023

 

6.4        Silent carrier state

 

6.4.1     Market Estimates & Forecast, 2016 – 2023

 

6.5        Trait

 

6.5.1     Market Estimates & Forecast, 2016 – 2023

 

Chapter 7.         Global Alpha Thalassemia Market, By Diagnosis

 

7.1        Introduction

 

7.2        Perinatal testing

 

7.2.1     Market Estimates & Forecast, 2017 – 2023

 

7.2.2     Complete blood count (CBC)

 

7.2.2.1     Market Estimates & Forecast, 2017 – 2023

 

7.2.3     DNA testing

 

7.2.3.1     Market Estimates & Forecast, 2017 – 2023

 

 

7.3        Prenatal testing

 

7.3.1     Market Estimates & Forecast, 2017 – 2023

 

7.3.2     Prenatal Genetic Testing

 

7.3.2.1     Market Estimates & Forecast, 2017 – 2023

 

7.3.3     Chorionic Villus sampling

 

7.3.3.1     Market Estimates & Forecast, 2017 – 2023

 

7.4       Pre-implantation

 

7.4.1     Market Estimates & Forecast, 2017 – 2023

 

Chapter 8.         Global Alpha Thalassemia Market, By Treatment

 

8.1        Introduction

 

8.2        Blood transfusions

 

8.2.1     Market Estimates & Forecast, 2017 – 2023

 

8.3        Iron chelation

 

8.3.1     Market Estimates & Forecast, 2017 – 2023

 

8.4        Bone marrow, or stem cell transplant

 

8.4.1     Market Estimates & Forecast, 2017 – 2023

 

8.5        Surgery

 

8.5.1     Market Estimates & Forecast, 2017 – 2023

 

8.6        Gene therapy

 

8.6.1     Market Estimates & Forecast, 2017 – 2023

 

Chapter 9.       Global Alpha Thalassemia Market, By End User

 

9.1      Introduction

 

9.2      Hospitals

 

9.2.1   Market Estimates & Forecast, 2017 – 2023

 

9.3      Biotechnological laboratories

 

9.3.1   Market Estimates & Forecast, 2017 – 2023

 

9.4      Diagnostic laboratories

 

9.4.1   Market Estimates & Forecast, 2017 – 2023

 

9.5      Educational research institutes

 

9.5.1   Market Estimates & Forecast, 2017 – 2023

 

9.6      Pharmaceutical industries

 

9.6.1   Market Estimates & Forecast, 2017 – 2023

 

9.7      Others

 

Chapter. 10       Global Alpha Thalassemia Market, By Region

 

10.1      Introduction

 

10.2      Americas

 

10.2.1   North America

 

10.2.1.1 U.S.

 

10.2.1.2 Canada

 

10.2.2   South America

 

10.3      Europe

 

10.3.1   Western Europe

 

10.3.1.1 Germany

 

10.3.1.2 France

 

10.3.1.3 Italy

 

10.3.1.4 Spain

 

10.3.1.5 U.K

 

10.3.1.6 Rest of Western Europe

 

10.3.2   Eastern Europe

 

10.4      Asia Pacific

 

10.4.1   Japan

 

10.4.2   China

 

10.4.3   India

 

10.4.4   Australia

 

10.4.5   Republic Of Korea

 

10.4.6   Rest of Asia Pacific

 

10.5      The Middle East & Africa

 

10.5.1   United Arab Emirates

 

10.5.2   Saudi Arabia

 

10.5.3   Rest of the Middle East & Africa

 

Chapter 11        Company Landscape   

 

11.1      Introduction     

 

11.2      Market Share Analysis 

 

11.3      Key Development & Strategies

 

11.3.1   Key Developments      

 

Chapter 12        Company Profiles       

 

12.1      GlaxoSmithKline Plc

 

12.1.1   Company Overview     

 

12.1.2   Treatment Overview        

 

12.1.3   Financials       

 

12.1.4   SWOT Analysis

 

12.2      Celgene Corporation

 

12.2.1   Company Overview     

 

12.2.2   Treatment Overview        

 

12.2.3   Financial Overview       

 

12.2.4   Key Developments      

 

12.2.5   SWOT Analysis

 

12.3      Bellicum Pharmaceuticals

 

12.3.1   Company Overview     

 

12.3.2   Treatment Overview        

 

12.3.3   Financial Overview

 

12.3.4   Key Development        

 

12.3.5   SWOT Analysis

 

12.4      Lonza group

 

12.4.1   Company Overview     

 

12.4.2   Treatment/Business Segment Overview   

 

12.4.3   Financial Overview       

 

12.4.4   Key Development        

 

12.4.5   SWOT Analysis

 

12.5      Acceleron Pharma

 

12.5.1   Company Overview     

 

12.5.2   Treatment Overview        

 

12.5.3   Financial Overview       

 

12.5.4   Key Developments      

 

12.6      BlueBird Bio

 

12.6.1   Company Overview     

 

12.6.2   Treatment Overview        

 

12.6.3   Financial Overview       

 

12.6.4   Key Developments      

 

12.7      Sangamo Biosciences

 

12.7.1   Overview         

 

12.7.2   Treatment Overview        

 

12.7.3   Financials       

 

12.7.4   Key Developments      

 

12.7.5   SWOT Analysis

 

12.8      Johnson & Johnson

 

12.8.1   Company Overview     

 

12.8.2   Treatment/Business Segment Overview   

 

12.8.3   Financial Overview       

 

12.8.4   Key Development        

 

12.8.5   SWOT Analysis

 

12.9      Merck & Co Inc.

 

12.9.1   Company Overview     

 

12.9.2   Treatment Overview        

 

12.9.3   Financial Overview       

 

12.9.4   Key Developments      

 

12.10    Others

 

Chapter 13        MRFR Conclusion       

 

13.1      Key Findings   

 

13.1.1   From CEO’s View Point

 

13.1.2   Unmet Needs of the Market     

 

13.2      Key Companies to Watch        

 

13.3      Prediction of Pharmaceutical Industry

 

Chapter 14        Appendix

 

LIST OF TABLES

 

Table 1             Alpha Thalassemia Industry Synopsis, 2017 – 2023

 

Table 2             Alpha Thalassemia Market Estimates and Forecast, 2017 – 2023, (USD Million)

 

Table 3             Alpha Thalassemia Market by Region, 2017 – 2023, (USD Million)

 

Table 4             Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)

 

Table 5             Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)

 

Table 6             Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)

 

Table 7             Alpha Thalassemia Market by End Users, 2017 – 2023, (USD Million)

 

Table 8             North America Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)

 

Table 9            North America Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)

 

Table 10            North America Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)

 

Table 11            North America Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)

 

Table 12            US Alpha Thalassemia Market By Type, 2017 – 2023, (USD Million)

 

Table 13            US Alpha Thalassemia Market By Diagnosis, 2017 – 2023, (USD Million)

 

Table 14            US Alpha Thalassemia Market By Treatment, 2017 – 2023, (USD Million)

 

Table 15            US Alpha Thalassemia Market By End User, 2017 – 2023, (USD Million)

 

Table 16            Canada Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)

 

Table 17            Canada Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)

 

Table 18            Canada Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)

 

Table 19            Canada Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)

 

Table 20            South America Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)

 

Table 21            South America Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)

 

Table 22            South America Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)

 

Table 23            South America Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)

 

Table 24            Europe Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)

 

Table 25            Europe Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)

 

Table 26            Europe Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)

 

Table 27            Europe Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)

 

Table 28            Western Europe Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)

 

Table 29            Western Europe Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)

 

Table 30            Western Europe Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)

 

Table 31            Western Europe Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)

 

Table 32            Eastern Europe Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)

 

Table 33            Eastern Europe Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)

 

Table 34            Eastern Europe Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)

 

Table 35            Eastern Europe Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)

 

Table 36            Asia Pacific Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)

 

Table 37            Asia Pacific Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)

 

Table 38            Asia Pacific Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)

 

Table 39            Asia Pacific Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)

 

Table 40           The Middle East & Africa Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)

 

Table 41            The Middle East & Africa Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)

 

Table 42            The Middle East & Africa Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)

 

Table 43            The Middle East & Africa Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)

 

LIST OF FIGURES

 

Figure 1            Research Process

 

Figure 2            Segmentation for Alpha Thalassemia Market

 

Figure 3            Segmentation Market Dynamics for Alpha Thalassemia Market

 

Figure 4            Global Alpha Thalassemia Market Share, By Type 2016

 

Figure 5            Global Alpha Thalassemia Market Share, By Diagnosis 2016

 

Figure 6            Global Alpha Thalassemia Market Share, By Treatment, 2016

 

Figure 9            Global Alpha Thalassemia Market Share, By End Users, 2016

 

Figure 10          Global Alpha Thalassemia Market Share, By Region, 2016

 

Figure 11          North America Alpha Thalassemia Market Share, By Country, 2016

 

Figure 12          Europe Alpha Thalassemia Market Share, By Country, 2016

 

Figure 13          Asia Pacific Alpha Thalassemia Market Share, By Country, 2016

 

Figure 14          the Middle East & Africa Alpha Thalassemia Market Share, By Country, 2016

 

Figure 15          Global Alpha Thalassemia Market: Company Share Analysis, 2016 (%)

 

Figure 16          GlaxoSmithKline Plc: Key Financials

 

Figure 17          GlaxoSmithKline Plc: Segmental Revenue

 

Figure 18          GlaxoSmithKline Plc: Geographical Revenue

 

Figure 19          Celgene Corporation: Key Financials

 

Figure 20          Celgene Corporation: Segmental Revenue

 

Figure 21          Celgene Corporation: Geographical Revenue

 

Figure 22          Bellicum Pharmaceuticals: Key Financials

 

Figure 23          Bellicum Pharmaceuticals: Segmental Revenue

 

Figure 24          Bellicum Pharmaceuticals: Geographical Revenue

 

Figure 25          Lonza group: Key Financials

 

Figure 26          Lonza group: Segmental Revenue

 

Figure 27          Lonza group: Geographical Revenue

 

Figure 28          Acceleron Pharma: Key Financials

 

Figure 29          Acceleron Pharma: Segmental Revenue

 

Figure 30          Acceleron Pharma: Geographical Revenue

 

Figure 32          BlueBird Bio: Key Financials

 

Figure 33          BlueBird Bio: Segmental Revenue

 

Figure 34          BlueBird Bio: Geographical Revenue

 

Figure 35          Sangamo Biosciences: Key Financials

 

Figure 36          Sangamo Biosciences: Segmental Revenue

 

Figure 37          Sangamo Biosciences: Geographical Revenue

 

Figure 38          Johnson & Johnson: Key Financials

 

Figure 39          Johnson & Johnson: Segmental Revenue

 

Figure 40          Johnson & Johnson: Geographical Revenue

 

Figure 41          Merck & Co Inc.: Key Financials

 

Figure 42          Merck & Co Inc.: Segmental Revenue

 

Figure 43          Merck & Co Inc.: Geographical Revenue